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Summary One hundred and seventy-eight patients with non metastatic inflammatory breast cancer (IBC)
have been treated at the Centre H. Becquerel. Median follow up is 67 months (6-178). Every patient received
neoadjuvant chemotherapy (mean number of cycles = 4; range: 2-8), followed by a loco regional treatment
(radiotherapy = XRT or modified radical mastectomy = S), followed by adjuvant chemotherapy. During this
period, the types of chemotherapy and locoregional treatment have been the following: Study I: 64 patients
treated with CMF or AVCF and XRT; Study II: 83 patients, treated with either AVCF, FAC or VAC
followed by S (n = 38) or XRT (n = 22) in case of complete or partial response, or followed by XRT (23) in
case of initial supraclavicular lymph node involvement or lack of response after chemotherapy; Study III: 31
patients treated with FEC-HD + Estrogenic recruitment followed by S and XRT after adjuvant chemotherapy,
except seven patients who received XRT (refusal of surgery). Although objective response rates (= 56.2, 73.5
and 93.5% for study I, II and III respectively) are statistically better in the 3rd study, this does not translate in
dramatically different disease free survival (median = 16.7, 19 and 22.2 months respectively for study I, II and
III) or overall survival (median = 25, 45.7 and 32.6 months respectively for study I, II and III). Analysis of
subset of patients without supra clavicular lymph node involvement where neoadjuvant chemotherapy
obtained at least a 50% response reveals a median disease free survivcal and median overall survival of
respectively 38.3 and 60.1 months for patients who underwent S vs 19 and 38.3 months for those who received
XRT (P = 0.15). These studies suggest that surgery has no deleterious effect on outcome of IBC. Advantage
on disease free survival or overall survival from intensive chemotherapy in IBC remains to be proven with
appropriate randomised trials.
Inflammatory adenocarcinoma of the breast is a rare disease
with severe prognostic implications due to an almost con-
stant metastatic evolution. The definition is mainly clinical
(Haagensen, 1971): enlargement, tenderness, firmness, redness
of the breast with usually no fever. A tumour may be
clinically detectable or not in the breast. With either surgery
or radiotheripy alone or the use of combination surgery and
radiotherapy, less than 15% of patients will survive at 5
years (Camp, 1976; Swain, 1989). Because of the high risk of
metastasis, a combined modality approach including chemo-
therapy is at the present time admitted worldwide (Hor-
tobagyi et al., 1986; Swain et al., 1989). This strategy has led
to a significant improvement in survival, with 30 to 50% of
the patients surviving beyond 5 years (Swain et al., 1989).
Achievement of a mastectomy specimen free of residual
macroscopic tumour after induction chemotherapy has been
shown to be an excellent indicator of a prolonged disease free
and overall survival (Feldman et al., 1986). Unfortunately,
this situation accounts for less than 20% of the patients
(Fastenberg et al., 1985; Israel et al., 1986; Maloisel et al.,
1990; Mignot et al., 1984; Schafer et al., 1987; Swain, 1987;
Swain et al., 1989; Thomas et al., 1990; Wiseman et al.,
1982). One area of research is to increase survival by the
search of more efficient induction chemotherapy regimens
yielding a higher histologic response rate. More aggressive
cytotoxic regimens using the concept of dose efficacy can be
tested for this goal. Moreover, the best loco regional treat-
ment is not determined with certainty at the present time for
patients who achieve a good objective response to neo-
adjuvant chemotherapy. For those patients, exclusive radio-
therapy remains the academic choice whereas surgery is
controversial.
We present here three consecutive studies conducted at the
H. Becquerel Cancer Center in 178 patients. The aim of these
studies was (1) to improve the response rate obtained with
neoadjuvant chemotherapy, (2) to obtain the best loco-
regional control of the disease, (3) to increase overall survival
and disease free survival of these patients with these com-
bined modality approaches.
Patients and methods
The 178 patients retained for this analysis represent 4% of
the newly diagnosed invasive non metastatic adenocar-
cinomas of the breast between January 1977 and February
1990 (n = 4,359). All of them meet the following criterias:
histologically proven invasive adenocarcinoma of one breast,
inflammatory signs (erythema + 'peau d'orange + increase of
the local heat) involving at least one third of the breast (T4d
of the 1988 UICC classification), no history of previous
malignancy, no prior specific treatment, serum bilirubin
<35 tmol 1', serum creatinine < 130timol 1-'. A positive skin
biopsy was not mandatory for the diagnosis since we con-
sidered as others (Fastenberg et al., 1985; Fields et al., 1989;
Hortobagyi et al., 1986; Lucas et al., 1978; Swain et al., 1989)
that inflammatory breast cancer is a clinical diagnosis rather
than a pathologic definition. Only some patients included in
the second study and all the patients of the third study had a
skin biopsy performed at the time of initial diagnosis
(n = 88). Cases with previous history of breast cancer,
bilateral breast cancer, prior history of heart failure or with
an history of another malignant tumour were not kept for
this analysis. This excludes also advanced breast cancer such
as scirrous or ulcerated cancers and also rapidly progressing
breast cancers without inflammatory signs. Since January
1977, every patient had a pretreatment check-up including
history and physical examination, bilateral mammographies,
chest X ray, bone scan, liver echography or CT scan, EKG
and echocardiography or radionuclide cardiac scan (since
1983), complete blood count, standard biological tests, car-
cinoembryonic antigen (until 1986), CA 15.3 (since 1987).
Estrogen and progesterone receptors were measured accord-
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ing to the coal-dextran technique for the patients of the
second and third study. Improvement in X-ray and echog-
raphic techniques and the use of more sensitive tumour
markers could have resulted in a more accurate staging for
the more recent patients.
Assessment of tumour response was performed at least
every two cycles with clinical examination and mammo-
graphies. All baseline investigations were repeated at the end
of the treatment.
Follow-up was every 3 months the first year, bi-annual for
the next 4 years and once a year therafter, with clinical
examination, chest X ray and biochemical screen. Mammo-
graphies were performed once a year. Locoregional or con-
trolateral relapses were confirmed by biopsies or unequivocal
radiological evidence.
First study
In January 1977, induction chemotherapy was introduced at
the Centre H. Becquerel before locoregional treatment. This
induction chemotherapy consisted either in CMF (n = 22;
until April 1979) or AVCF (n = 42) (see Table I) given for
three cycles. Retreatment was decided at day 28 if platelets
were> 100000 mm-3 and PNN>2000 mm-3. Loco regional
treatment consisted in every case in exclusive radiotherapy.
Surgery was only employed as a salvage treatment in case of
loco regional relapse after radiotherapy (n = 8). Maintenance
chemotherapy was the same as induction chemotherapy for
eight cycles. From January 1977 to June 1983 64 patients
have been included in this study (Chevallier et al., 1987).
Second study
Treatment modalities
The patients of each of the three groups were treated with a
combined modality approach. Induction chemotherapy was
always given first for an average of four cycles (range: 2-8).
Loco regional treatment consisted ofradiotherapy or surgery.
Radiotherapy as exclusive loco regional treatment employed
Cobalt 60 and delivered 60 grays to the tumour, the whole
breast and the axilla, 50 grays to the internal mammary
chain and 46 grays to the supraclavicular area. Ten Grays
per week were given in five fractions. Four to 6 weeks after
the first irradiation, a 20 grays boost was given to the breast
tumoural remainders. No chemotherapy was administered
during radiotherapy. Surgery consisted in every case of a
modified radical mastectomy with homolateral axillary
clearance. No conservative surgery was performed. Main-
tenance chemotherapy was administered only if induction
chemotherapy obtained at least a partial response and used
the same schedule as induction chemotherapy for an average
of four cycles (range: 0-12). No standard protocol was
adopted in the treatment of loco regional or distant recur-
rences: patients were given the most suitable therapy for their
state.
Between 1977 and 1990 modifications in the treatment
programme have been made in three steps.
From July 1983 to December 1987, a total of 83 patients
have been included in this second study. Because of the poor
results in loco regional control with high incidence of intra-
mammary remainders and loco regional relapses observed in
the first study (Chevallier et al., 1987), we decided to test the
value of surgery as loco regional treatment. This was done
for the patients with no supra clavicular lymph node involve-
ment achieving at least a good partial response with disap-
pearance of erythema after induction chemotherapy. This
chemotherapy consisted either of AVCF (n = 21) FAC
(n = 39) or VAC (n = 23) (see Table I). Two to six cycles
were given (average = four cycles). One patient received eight
cycles. Policy for retreatment at day 28 for the patients
treated with AVCF was the same as in the first study. The
same blood count criteria were used for the patients treated
with FAC or VAC but retreatment was planned to be at day
21 instead of day 28.
Twenty-three patients had either supra clavicular lymph
node involvement or achieved stabilisation or progressive
disease after induction therapy. These 23 patients received
exclusive radiotherapy for loco regional treatment.
Sixty patients without supra clavicular lymph node
involvement and who achieved at least a partial response
after neoadjuvant chemotherapy were either operated on
(n = 38) or received exclusive radiotherapy (n = 22). This
Table I Chemotherapy schedules employed in the three studies
Chemotherapy
regimen
CMF
AVCF
VAC
FAC
FEC-HD
Days
1 and 8
1 and 8
1 to 7
2
3 to 6
3 to 6
1 to 4
1 to 3
1 to 3
1 and 2
2 to 5
3 to 5
3 to 5
FEC 75 1
(Adjuvant) 1
I
Drugs and dosage
5 Fluoro Uracil 600mg/m2*
Methotrexate 40 mg/m2*
Cyclophosphamide 150mg/m2t
Doxorubicin 30mg/m2
Vincristin 1.4 mg/m2 (max = 2 mg)*
Cyclophosphamide 300 mg/m2* and
5 fluoro uracil 400mg/m2*
Vindesin 1 mg/m2*
Doxorubicin 15 mg/m2*
Cyclophosphamide 200 mg/m2
Doxorubicin 50 mg/m2*
5 Fluoro uracil 500mg/m2*
Cyclophosphamide 500 ng m2*
Ethinyl oestradiol 50fg TIDt
5 Fluoro uracil 750 mg/M2 (CIVI)
Epirubicin 35 mg/m2*
Cyclophosphamide 400 mg/m2*
Epirubicin 75 mg/m2*
5 Fluoro uracil 500mg/m2*
Cyclophosphamide 500 mg/m2*
TOTAL = 178
CIVI: continuous i.v. infusion. *: bolus i.v. infusion. t: given orally.
Number of
patients
22
63
23
39
31
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Factor studied
Number ofpatients
Table II Main characteristics of the patients
First study Secondstudy
64 83
Age at initial diagnosis
average (range)
Menopausal status at
initial diagnosis
-Pre
-Post
Clinical size of tumour (mm)
average (range)
Mammographic size of the tumour (mm)
average (range)
Extent of inflammatory signs
-Limited
-Diffuse
Clinical lymph node involvement
-NO
-Nlb
-N2
-Supra clavicular
Histopathological grading
-1
-2
-3
-Not done
ER
average (range)
PR
49.4 49.3 50.8
(25-76) (24-76) (37-68)
33
31
85.5
(30-160)
62.1
(25-150)
35
29
40
11
8
2
14
10
38
53
30
70.9
(30-120)
50.7
(15-100)
56
27
13
52
10
8
7
27
14
35
15
16
65.9
(0-110)
46.7
(0-95)
16
15
4
23
2
2
4
16
6
5
NA 18.1 3.9
(1-825) (1-30)
NA 10.0 8.5
(1-275) (1-30)
Cutaneous Biopsy
-Negative 41 20
-Positive - 18 9
-Not done 64 24 2
NA: not available. ER: estrogen receptor. PR: progesterone receptor.
Table III Overall response rates observed after induction chemotherapy
Type ofinduction chemotherapy
First study Secondstudy Third study
Response observed CMF AVCF FAC VAC AVCF FEC-HD
CR 2 2 4 2 0 8
PR 9 23 25 15 15 21
SD 10 11 9 5 6 2
PD 1 6 1 1 0 0
TOTAL 22 42 39 23 21 31
CR: complete response. PR: partial response. SD: stable disease. PD: progressive
disease.
choice was not randomised but left to the clinician and
patient choice. No adjuvant radiotherapy was given in case
of surgery.
Maintenance chemotherapy was the same as induction
chemotherapy for four cycles.
Third study
From January 1988 to February 1990, 31 patients entered
this study aiming at finding a more aggressive cytotoxic
regimen using the concept of dose efficacy. This was the
reason for our FEC-HD pilot trial (Chevallier et al., 1990).
Estrogenic recruitment was introduced in the combination
given the impressive results obtained by other teams (Conte
et al., 1987; Swain et al., 1987). High response rates had been
reported with continuous 5FU infusion in pretreated metas-
tatic breast cancer (Hansen et al., 1987). This was the reason
why we incorporated this drug with this particular modality
of administration in our induction regimen. Activity of cyclo-
phosphamide and epirubicin in inflammatory breast cancer
had already been reported (Gisselbrecht et al., 1989), but we
chose higher dosage of each drug.
Induction chemotherapy with FEC-HD lasted four cycles.
Retreatment at day 21 was decided if the platelets
were> 75,000mm3 and PNN> 1,500 mm-3. Loco regional
treatment policy was the same as in the second study. How-
ever all the patients without supra clavicular involvement
who achieved at least partial response after induction therapy
were proposed surgery. Seven refused and received radio-
therapy. Adjuvant chemotherapy consisted in four cycles of
FEC 75 (see Table I). Adjuvant radiotherapy was given after
adjuvant chemotherapy to the patients who underwent
surgery.
Third study
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Table IV Toxicities encountered in the three studies
WHO grade
Event 0 1 2 3 4 Total
Stomatitis
Study 1 49 12 3 0 0 64
Study 2 56 16 9 2 0 83
Study 3 0 8 15 7 1 31
Febrile event
Study 1 54 4 5 1 0 64
Study 2 65 9 7 1 1 83
Study 3 3 8 14 6 0 31
Day 21: Neutropenia
Study 1 40 19 3 2 0 64
Study 2 48 24 6 4 1 83
Study3 19 3 5 1 3 31
Day 21: Thrombocytopenia
Study I 0 0 0 0 0 64
Study 2 0 0 0 0 0 83
Study 3 29 0 0 2 0 31
Day 21: Anemia
Study I NA NA NA NA NA 64
Study 2 69 13 1 0 0 83
Study 3 3 14 10 3 1 31
NA = not available.
Table V Results on disease free and overall survival
Overall survival Diseasefree survival
Median 5 years 10years Median 5 years 10 years
Overall 37 months 32% 23% 18.9 months 22% 13%
Study 1 25 months 29% 20% 16.7 months 18% 11%
Study 2 45.9 months 39% NA 19 months 28% NA
Study 3 Not reached NA NA 22.4 months NA NA
NA: not available.
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Figure 1 Disease free and overall survival curves of the 178 patients. Curve 1: Overall survival. Curve 2: Disease free survival.
Statistical analysis
Results were last updated in August 1992. Response rates
were estimated at the end of induction chemotherapy.
Overall response rates were determined taking into account
both the breast tumour, the lymph nodes and the
inflammatory signs. Response rates and toxicity were
reported using the WHO criterias (Miller et al., 1981).
Disease-free survival was defined as the time elapsed between
date of remission and date of first relapse wherever this
i598 B. CHEVALLIER et al.
100 L~
It I RuA
L sL 75t
I S
L I1-t~
ni -1
C,) L l '4-
I 8 2
25 1 .2
0
0 60
Months
120
Figure 2 Overall survival curves of the patients included in study I (curve 1), study II (curve 2) and study III (curve 3).
relapse might be. We chose the date of remission to be the
date of surgery or the date of last day of radiotherapy.
Overall survival was the time separating date of initial diag-
nosis and date of last known to be alive/or date of death,
whatever might be the cause of death. The survival curves
have been established according to the Kaplan and Meier
method (Kaplan et al., 1957). The degree of signification
between the curves (P) was calculated using the Log rank test
(Mantel, 1966). Percentage differentials were tested by app-
lication of the X2 test.
Results
The main characteristics of the patients are shown in Table
II. No statistical difference was seen between the three groups
of patients when considering menopausal status, age at diag-
nosis, extent of inflammatory signs, clinical lymph node
involvement, estrogen and progesterone receptors, histo-
pathological grading. Average size of the tumour determined
clinically and at mammography was larger in group 1 than
a)
a)
a)
.0 0,)
C',
both groups 2 and 3 (P<0.05). Similarly when we consider
the main prognostic factors, no statistical difference was
observed between the patients of the second study who
received surgery or radiotherapy after efficient induction
chemotherapy. Eighty eight patients had a skin biopsy per-
formed at the time of initial diagnosis, 61 had no tumoural
involvement of the dermal lymphatics and 27 had a positive
result. There was no statistical difference in disease free
survival and in overall survival between the patients with
positive or negative skin biopsy.
The objective response rate (RR) between CMF and
AVCF in study I was not statistically different (RR =
50% ± 22% vs 58.5% ± 15.5%; P= 0.46). The same was
observed between AVCF, FAC and VAC in study II (RR =
71.5% ± 17.5% vs 74% ± 13% vs 74% ± 16% respectively;
P = 0.96). This prompted us to pool the patients of study I
and those of study II and to analyse and compare the results
of the patients included in the first, the second and the third
study, whatever the induction chemotherapy might be. The
objective response rate (CR + PR) was 53.1% in the first
study, 73.5% in the second one and 93.5% in the third study
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Figure 3 Disease free survival curves of the patients included in study I (curve l), study II (curve 2) and study III (curve 3).
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Figure 4 Overall survival curves of the patients of study II with no supra clavicular involvement and good partial response after
induction chemotherapy. Loco regional treatment is surgery (curve 1) and radiotherapy (curve 2).
(Table III). The difference is statistically significant between
the first and the second study (P = 0.028), between the
second and the third study (P = 0.019) and between the first
and the third study (P = 0.0002). Hematologic and non
hematologic toxicities from these regimens are listed in Table
IV. They were greater in the third study than in the second
and also greater in the second study than in the first.
The overall survival and disease free survival of the 178
patients are shown in Figure 1. The overall survival and
disease free survival of the patients treated in the first, the
second and the third study are shown in Figure 2 and 3
respectively. The median disease free survival is 16.7, 19 and
22.2 months for the groups 1, 2 and 3 respectively. The
median overall survival is 25, 45.7 and 32.6 months for
groups 1, 2 and 3 respectively.
In study II, when we consider the 60 patients with no
supraclavicular lymph node involvement who achieved at
least a partial response after induction chemotherapy, overall
survival and disease free survival (whatever the site of relapse
4)
c)
Lo
0)
a)
U)
:0
may be) after surgery or radiotherapy are shown in Figure 4
and 5 respectively. The median disease free survival is 37.8
months for the patients who underwent surgery and 19
months for those who received radiotherapy (P<0.05). The
median overall survival is 66.3 months for the surgery group
and 38.3 months for the radiotherapy group (P = NS). In
this particular subset ofpatients, the number of loco regional
relapses was 13 and 11 after surgery and radiotherapy respec-
tively. Thus, the median relapse free survival time is not
reached for the patients treated with surgery and is 35 months
for those who received radiotherapy (P = NS) (Figure 6).
Discussion
This paper summarises an experience from one center of
combined modality approach of unilateral non metastatic
breast cancer. Comparison between our three studies con-
ducted within 13 years have been made. We know that
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Figure 5 Disease free survival curves of the patients of study II with no supra clavicular involvement and good partial response
after induction chemotherapy. Loco regional treatment is surgery (curve 1) and radiotherapy (curve 2).
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Figure 6 Local regional relapse free survival curves of the patients of study II with no supra clavicular involvement and good
partial reponse after induction chemotherapy. Loco regional treatment is surgery (curve 1) and radiotherapy (curve 2).
caution should be kept because of the historical comparisons
we made. However, inflammatory breast cancer is a rare
disease and historical controls remain our best approach. No
randomised trial have been published so far in this field.
The patients included in these three studies are superim-
posable to those reported in other series of inflammatory
breast cancer (Fastenberg et al., 1985; Feldman et al., 1986;
Fields et al., 1989; Gisselbrecht et al., 1989; Israel et al.,
1986; Maloisel et al., 1990; Mignot et al., 1984; Rouesse et
al., 1990; Schafer et al., 1987; Swain et al., 1987; Swain et al.,
1989; Thoms et al., 1990; Wiseman et al., 1982). All other
advanced breast cancers were excluded from this study. A
positive skin biopsy was not mandatory as an inclusion
criteria since the diagnosis ofinflammatory breast cancer can
be accurately be made by clinical examination only
(Fastenberg et al., 1985; Fields et al., 1989; Haagensen, 1971;
Hortobagyi et al., 1986; Lucas et al., 1978; Swain et al.,
1989). However for those patients who underwent a skin
biopsy at the time of initial diagnosis, no difference in disease
free survival or in overall survival could be pointed out when
a dermal lymphatic involvement was noted or not.
The treatment chosen for the first study is a very classical
one and has been applied similarly by other teams worldwide
with similar results (Chauvergne et al., 1981; Mourali et al.,
1982; Palangie et al., 1985; Rouesse et al., 1986; Swain et al.,
1989). The use of surgery for loco regional treatment is more
controversial in inflammatory breast cancer. This has how-
ever been applied less often by other teams and the results
already published compare with ours (Calderoli et al., 1988;
Conte et al., 1987; Feldman et al., 1986; Hagelberg et al.,
1984; Israel et al., 1986; Maloisel et al., 1990; Mignot et al.,
1984; Mourali et al., 1982; Noguchi et al., 1988; Schafer et
al., 1987; Swain et al., 1989; Thoms et al., 1990).
Very few teams have introduced intensive chemotherapy in
the treatment of inflammatory breast cancer as we did in our
third study (Gisselbrecht et al., 1989). The therapeutic
schedule we chose for this induction chemotherapy had never
been reported previously. Estrogenic recruitment was intro-
duced in the combination given the impressive results
obtained by other teams (Conte et al., 1987; Swain et al.,
1987) in both advanced and inflammatory breast cancer.
The clinical and mammographic response rate observed
was better in the third study than in the second one, and
better in the second study than in the first one. This is
statistically significant. High dose chemotherapy regimen
seems thus to be correlated with a better response rate.
Although these are not randomised studies, the results seem
to point out a strong correlation between intensity of induc-
tion chemotherapy and tumour response. This could be an
additional evidence of relationship between dose and efficacy
to response rates in breast cancer as stated by Hryniuk and
colleagues (Hryniuk et al., 1987).
In spite of the better response rate observed in study II
and III compared to study I, we did not observe a major
difference in the median disease free survival or overall sur-
vival of the patients treated in these three studies. A slight
significant advantage was seen for disease free survival only
for the patients of the third study compared to the patients
of the first study. No plateauing of the curves has been seen.
However these results are disappointing since they seem to
indicate that overall survival and disease free survival are not
dramatically affected by the better responses observed with
intensive chemotherapy. Similar disappointing results have
been reported for chemosensitive solid tumours such as small
cell lung cancer (Klasa et al., 1991). One possible explanation
for the disappointing results we observed is that in our third
study, estrogenic recruitment could have stimulated a
tumoural resistant clone thus debasing the results on overall
and disease free survival. However such a conclusion on this
hypothesis has not been retained by other teams (Conte et
al., 1987; Swain et al., 1987). Because of the results published
in the literature, some consider that there is no convincing
indication for the routine use of chemohormonal syn-
chronisation approach at the present time (Davidson et al.,
1987). Finally we believe that the superiority of intensive
induction chemotherapy over classical regimen would be
tested in a prospective randomised manner to test the impact
of such treatment on overall survival and disease free survival.
In our second study, the results obtained by surgery and
radiotherapy on loco regional relapse free and overall sur-
vival are not statistically significant. The curves show how-
ever a constant advantage for surgery. The difference is
statistically significant in favour of surgery for disease free
survival whatever the site of relapse may be. These results
demonstrate that there is no reason to exclude surgery as
loco regional treatment for inflammatory breast cancer
patients suitable for surgery, with no supra clavicular lymph
node involvement at the time of initial diagnosis and who
achieve at least a good partial response after induction
chemotherapy. Similar results have been published by three
other teams (Fields et al., 1989; Hagelberg et al., 1984;
Mourali et al., 1982).INFLAMMATORY NON METASTATIC BREAST CANCER 601
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